Literature DB >> 23543817

Clinicopathologic assay of 15 tumor resections in a family with neurofibromatosis type 2.

Salvatore Di Maio1, Goran Mrak, Gordana Juric-Sekhar, Donald Born, Alessandra Mantovani, Laligam N Sekhar.   

Abstract

The objective of this study is the management of multiple family members with multiple neurofibromatosis type 2 (NF2) related tumors of the skull base that can be challenging, on purely technical, decision-making, and ethical levels. These issues are addressed in this manuscript based on an experience treating an unique large family with NF2. A retrospective chart review was performed, reviewing clinical, radiological, surgical, and pathological data. A unique family of 17 siblings, whose father was the proband as a sporadic mutation is reported. Over a 4-month period, five of eight affected siblings underwent 12 procedures for resection of 15 different NF2-related tumors. This single family experience of NF2-related skull base tumors underscores the importance of preservation of function and quality of life as the major determinants of treatment success.

Entities:  

Keywords:  NF2 associated tumors; ethics; meningioma; neurofibromatosis type 2; quality of life; vestibular schwannoma

Year:  2012        PMID: 23543817      PMCID: PMC3424622          DOI: 10.1055/s-0032-1301394

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  29 in total

1.  Management strategy of vestibular schwannoma in neurofibromatosis type 2.

Authors:  Haitham Ahmad Odat; Enrico Piccirillo; Giuliano Sequino; Abdelkader Taibah; Mario Sanna
Journal:  Otol Neurotol       Date:  2011-09       Impact factor: 2.311

2.  The neuroimaging and clinical spectrum of neurofibromatosis 2.

Authors:  V F Mautner; M Lindenau; M E Baser; W Hazim; M Tatagiba; W Haase; M Samii; R Wais; S M Pulst
Journal:  Neurosurgery       Date:  1996-05       Impact factor: 4.654

3.  Aligning ethics with medical decision-making: the quest for informed patient choice.

Authors:  Benjamin Moulton; Jaime S King
Journal:  J Law Med Ethics       Date:  2010       Impact factor: 1.718

4.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

Authors:  J A Trofatter; M M MacCollin; J L Rutter; J R Murrell; M P Duyao; D M Parry; R Eldridge; N Kley; A G Menon; K Pulaski
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

Review 5.  Neurofibromatosis type 2.

Authors:  Gareth R Evans; Simon K W Lloyd; Richard T Ramsden
Journal:  Adv Otorhinolaryngol       Date:  2011-02-24

6.  Early proactive management of vestibular schwannomas in neurofibromatosis type 2.

Authors:  D E Brackmann; J N Fayad; W H Slattery; R A Friedman; J D Day; W E Hitselberger; R M Owens
Journal:  Neurosurgery       Date:  2001-08       Impact factor: 4.654

7.  Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2.

Authors:  M Samii; C Matthies; M Tatagiba
Journal:  Neurosurgery       Date:  1997-04       Impact factor: 4.654

Review 8.  The diagnosis and management of neurofibromatosis 2 in childhood.

Authors:  M MacCollin; V F Mautner
Journal:  Semin Pediatr Neurol       Date:  1998-12       Impact factor: 1.636

9.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

Review 10.  The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene.

Authors:  Michael E Baser
Journal:  Hum Mutat       Date:  2006-04       Impact factor: 4.878

View more
  2 in total

Review 1.  Anterolateral meningioma of the foramen magnum and high cervical spine presenting intradural and extradural growth in a child: case report and literature review.

Authors:  Alkinoos Athanasiou; Ioannis Magras; Panagiotis Sarlis; Evangelos Spyridopoulos; Konstantinos Polyzoidis
Journal:  Childs Nerv Syst       Date:  2015-06-16       Impact factor: 1.475

2.  Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review.

Authors:  Pengfei Liu; Qingyu Yao; N A Li; Yongliang Liu; Yuguo Wang; Meng Li; Zefu Li; Jianmin Li; Gang Li
Journal:  Oncol Lett       Date:  2016-03-17       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.